The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Nektar said it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and reagent ...

SARANAC LAKE — Ampersand Biosciences and Trudeau Institute have been awarded more than $1 million to study infectious diseases. A $1,084,824 Phase II Small Business Innovative Research grant ...

BOSTON, Oct. 31, 2024 /PRNewswire/ -- For the third consecutive year, Ampersand Capital Partners has been named to Inc.'s 2024 Founder-Friendly Investors list, which honors the private equity and ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

Ampersand reaches 1150 bikes on the roads of Nairobi Expansion underscores company's commitment to cutting carbon emissions and driving clean economic prosperity across Africa Nairobi – Ampersand, ...

Nektar Therapeutics has a 12 month low of $0.41 and a 12 month high of $1.93. The stock’s 50 day moving average price is $1.28 and its 200 day moving average price is $1.34.